Dataset from APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007102
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in
patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term
follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants
who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.
创建时间：
2026-03-05
